Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV to Induce a Protective T-cell 'Vaccinal Effect' - a Randomised Phase II Clinical Trial

NCT07054931 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT07054931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07054931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV to Induce a Protective T-cell 'Vaccinal Effect' - a Randomised Phase II Clinical Trial
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Recruiting
Start date
September 5, 2025
Completion date
June 30, 2028
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv